Analyst Robert Wasserman from Benchmark Co. maintained a Buy rating on Ligand Pharma and keeping the price target at $220.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Wasserman has given his Buy rating due to a combination of factors including Ligand Pharma’s promising financial forecasts and strategic investments. The company has reiterated its guidance for 2025, projecting revenues between $225-$235 million and adjusted EPS of $7.40-$7.65. Additionally, initial forecasts for 2026 suggest further growth with revenues expected to reach $245-$285 million and earnings of $8.00-$9.00. These projections indicate a strong financial outlook, supporting the Buy rating.
Another reason for the positive rating is Ligand’s strategic investments and partnerships, particularly with Pelthos Therapeutics. The company’s equity portfolio, valued at $186 million, and its deployable capital of $1 billion are significant assets. Furthermore, successful product launches and potential market expansions, such as Travere’s Filspari and Merck’s investment in Verona Pharma, are expected to drive royalty revenues and R&D catalysts. These factors, combined with a projected 23% growth rate through 2030, underpin Wasserman’s confidence in Ligand’s future performance.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $231.00 price target.